CN101568331A - 减少或缓解消化道炎症的方法 - Google Patents

减少或缓解消化道炎症的方法 Download PDF

Info

Publication number
CN101568331A
CN101568331A CNA2007800394181A CN200780039418A CN101568331A CN 101568331 A CN101568331 A CN 101568331A CN A2007800394181 A CNA2007800394181 A CN A2007800394181A CN 200780039418 A CN200780039418 A CN 200780039418A CN 101568331 A CN101568331 A CN 101568331A
Authority
CN
China
Prior art keywords
purposes
acid
ethylamino
carboxyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800394181A
Other languages
English (en)
Chinese (zh)
Inventor
路易斯·安东尼·塔尔塔利亚
托马斯·迈克尔·巴尔内斯
罗伯特·马克·库珀史密斯
斯克特·爱德华·莫尔斯特伦
大卫·威廉·怀特
多米尼克·皮卡雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Ore Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ore Pharmaceuticals Inc filed Critical Ore Pharmaceuticals Inc
Publication of CN101568331A publication Critical patent/CN101568331A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CNA2007800394181A 2006-09-08 2007-09-07 减少或缓解消化道炎症的方法 Pending CN101568331A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US60/825,075 2006-09-08
US82780706P 2006-10-02 2006-10-02
US60/827,807 2006-10-02

Publications (1)

Publication Number Publication Date
CN101568331A true CN101568331A (zh) 2009-10-28

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800394181A Pending CN101568331A (zh) 2006-09-08 2007-09-07 减少或缓解消化道炎症的方法

Country Status (11)

Country Link
US (1) US20080234345A1 (cg-RX-API-DMAC7.html)
EP (1) EP2059234B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010502736A (cg-RX-API-DMAC7.html)
CN (1) CN101568331A (cg-RX-API-DMAC7.html)
AT (1) ATE531362T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007292247A1 (cg-RX-API-DMAC7.html)
CA (1) CA2662535A1 (cg-RX-API-DMAC7.html)
DK (1) DK2059234T3 (cg-RX-API-DMAC7.html)
ES (1) ES2376493T3 (cg-RX-API-DMAC7.html)
IL (1) IL197362A0 (cg-RX-API-DMAC7.html)
WO (1) WO2008031014A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AU2009223644A1 (en) * 2008-03-10 2009-09-17 Ore Pharmaceuticals Inc. Therapy for disorders of the proximal digestive tract
US20100204286A1 (en) * 2009-02-12 2010-08-12 Donahue Stephen R Method for reducing gastrointestinal adverse effects of cytotoxic agents
JP5845171B2 (ja) * 2010-03-04 2016-01-20 大日本住友製薬株式会社 炎症性腸疾患用薬剤
PL2544679T3 (pl) 2010-03-12 2019-10-31 Omeros Corp Inhibitory PDE10 oraz powiązane kompozycje i sposoby
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
CA2980801A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
TR200103094T2 (tr) 1999-04-30 2002-03-21 Millennium Pharmaceuticals, Inc. ACE-2 inhibe eden bileçikler ve bunlarìn kullanìm y”ntemi
WO2002098448A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
PL378108A1 (pl) * 2003-02-14 2006-03-06 Combinatorx, Incorporated Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
WO2008031013A1 (en) * 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
ATE531362T1 (de) 2011-11-15
EP2059234B1 (en) 2011-11-02
EP2059234A1 (en) 2009-05-20
DK2059234T3 (da) 2011-11-28
CA2662535A1 (en) 2008-03-13
IL197362A0 (en) 2009-12-24
AU2007292247A1 (en) 2008-03-13
US20080234345A1 (en) 2008-09-25
WO2008031014A1 (en) 2008-03-13
ES2376493T3 (es) 2012-03-14
JP2010502736A (ja) 2010-01-28
AU2007292247A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
CN101568331A (zh) 减少或缓解消化道炎症的方法
US7842709B2 (en) Method for treating inflammatory diseases of the digestive tract
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
US20120009183A1 (en) Method for treatment of pancreatitis
JP2018138602A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
CN104640546A (zh) 常山酮的剂型以及使用方法
CN108653272A (zh) 青蒿素衍生物治疗炎症性肠病的医学用途
TW202027745A (zh) 用於治療發炎病症之組成物與方法
JP2018039831A (ja) 排尿頻度を減少させるための医薬製剤およびその使用の方法
CN103037901B (zh) 抑制cd36以控制肥胖和胰岛素敏感性
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
Hirano et al. Eosinophilic esophagitis
US12478627B2 (en) Irsogladine for the treatment of eosinophilic gastrointestinal diseases
Legerton III et al. Systemic sclerosis (scleroderma): clinical management of its major complications
ES2968628T3 (es) Rebamipida para uso en prevención y tratamiento de la enfermedad de Crohn
JP2011513491A (ja) 近位消化管の障害の治療
Dureja et al. Advanced drug delivery systems for colonic disorders
Denton et al. Raynaud’s Phenomenon and Scleroderma
CN111184726A (zh) β-内酰胺类化合物的应用
Simpson Refractory gastro-oesophageal reflux disease and laryngopharyngeal reflux-use the bottom up approach
Cozzi et al. Systemic Sclerosis
WO2006046746A1 (ja) 内臓痛予防・治療剤
EA030590B1 (ru) Применение тиазолопиримидинона для лечения воспалительного заболевания кишечника
Ayer et al. Investigational Therapies for Scleroderma
JP2004339151A (ja) 癌転移抑制剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091028